The next generation biopharmaceuticals

Affibody AB receives SwedenBIO award 2013

2013-05-22

Solna, Sweden, May 22, 2013. Affibody wins SwedenBIO Award 2013 for its unique business model.

Affibody received the SwedenBIO Award 2013 at life sciences industry organization
SwedenBIO’s annual conference in Stockholm on May 21, 2013. The award is the
industry’s own award which aims to focus the attention on Swedish life science
companies that have achieved significant national and international recognition
during the previous year.

During
2012 Affibody took several critical steps forward and saw its revenues grow
significantly. Additionally business development activities yielded two new key
collaborations during the year including the company’s first clinical stage
collaboration.

Commenting
on the award, David Bejker, Chief Executive Officer of Affibody AB, said: “We are thrilled to win this award. It is
rewarding for me and my colleagues to receive this acknowledgement for our work
in the past few years. Our increasing number of collaboration partners
validates our unique platforms that are products of world leading Swedish
research. Looking ahead we see great opportunity to further expand our business
and continue to create value from our technology platforms.

Further
information about the award can be found in the attached press release from
SwedenBIO (in Swedish).

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)